Samidorphan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Samidorphan
DrugBank Accession Number
DB12543
Background

Samidorphan has been used in trials studying the treatment of Schizophrenia, Alcohol Dependence, and Binge Eating Disorder.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 370.449
Monoisotopic: 370.189257325
Chemical Formula
C21H26N2O4
Synonyms
  • Samidorphan
External IDs
  • ALKS 33
  • ALKS-33
  • RDC-0313
  • RDC-0313-00

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AlfentanilThe therapeutic efficacy of Alfentanil can be decreased when used in combination with Samidorphan.
BenzhydrocodoneThe therapeutic efficacy of Benzhydrocodone can be decreased when used in combination with Samidorphan.
BuprenorphineThe therapeutic efficacy of Buprenorphine can be decreased when used in combination with Samidorphan.
ButorphanolThe therapeutic efficacy of Butorphanol can be decreased when used in combination with Samidorphan.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Samidorphan.
DextropropoxypheneThe therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Samidorphan.
DezocineThe therapeutic efficacy of Dezocine can be decreased when used in combination with Samidorphan.
DiamorphineThe therapeutic efficacy of Diamorphine can be decreased when used in combination with Samidorphan.
DihydrocodeineThe therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Samidorphan.
DiphenoxylateThe therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Samidorphan.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Naphthalenecarboxamides / Benzazocines / Isoquinolones and derivatives / Tetralins / Salicylic acid and derivatives / 1-hydroxy-4-unsubstituted benzenoids / Aralkylamines / Piperidines / Vinylogous acids / Tertiary alcohols
show 10 more
Substituents
1,2-aminoalcohol / 1-hydroxy-4-unsubstituted benzenoid / 2-naphthalenecarboxamide / 2-naphthalenecarboxylic acid or derivatives / Alcohol / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7W2581Z5L8
CAS number
852626-89-2
InChI Key
RYIDHLJADOKWFM-MAODMQOUSA-N
InChI
InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
IUPAC Name
(1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4-carboxamide
SMILES
NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1

References

General References
Not Available
PubChem Compound
11667832
PubChem Substance
347828769
ChemSpider
23259667
BindingDB
50165049
ChEMBL
CHEMBL426084
ZINC
ZINC000028478244
Wikipedia
Samidorphan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlcohol Dependency1
2CompletedTreatmentAlcohol Use Disorder (AUD) / Schizophrenia1
2CompletedTreatmentBinge Eating Disorder (BED)1
2CompletedTreatmentSchizophrenia1
1CompletedNot AvailableCocaine Abuse1
1CompletedTreatmentAlcohol Dependency1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentSubstance-Related Disorders1
1, 2CompletedNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.629 mg/mLALOGPS
logP1.09ALOGPS
logP0.46ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)7.88ChemAxon
pKa (Strongest Basic)8.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area103.86 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.04 m3·mol-1ChemAxon
Polarizability39.26 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 22:47 / Updated on February 21, 2021 18:53